Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Theravance Biopharma Inc | TBPH | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.20 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 9.20 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 8.21 - 11.98 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 9.20 | USD |
Theravance Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 443.12M | 48.16M | - | 57.42M | -55.19M | -1.15 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Theravance Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TBPH Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.55 | 10.44 | 9.15 | 9.62 | 487,320 | -0.35 | -3.66% |
| 1 Month | 8.98 | 10.44 | 8.65 | 9.29 | 419,395 | 0.22 | 2.45% |
| 3 Months | 9.86 | 10.44 | 8.21 | 9.03 | 369,901 | -0.66 | -6.69% |
| 6 Months | 9.10 | 11.71 | 8.21 | 9.77 | 389,958 | 0.10 | 1.10% |
| 1 Year | 11.60 | 11.98 | 8.21 | 10.00 | 437,692 | -2.40 | -20.69% |
| 3 Years | 21.64 | 22.74 | 6.10 | 10.00 | 690,696 | -12.44 | -57.49% |
| 5 Years | 22.99 | 31.54 | 6.10 | 12.65 | 546,384 | -13.79 | -59.98% |
Theravance Biopharma Description
| Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. It develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). |
